Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin

Cancer Chemotherapy and Pharmacology
Wataru IchikawaRenzo Hirayama

Abstract

Ferredoxin reductase (FDXR) is a putative contributor to p53-mediated apoptosis from 5-fluorouracil (5-FU) through the generation of oxidative stress in the mitochondria. However, the influence of FDXR gene expression levels on the outcome of 5-FU chemotherapy has been relatively little studied. The aim of this study is to investigate the association between FDXR gene expressions and the clinical outcome when treated by 5-FU chemotherapy, as well as the correlation of FDXR gene expressions and p53 mutation. Pre-chemotherapeutic fresh frozen samples of 33 patients with metastatic colorectal cancer, who received bolus 5-FU and leucovorin (LV) as first line chemotherapy, were studied. FDXR gene expression and p53 mutation were evaluated by real-time RT-PCR and direct sequencing, respectively. FDXR gene expression was significantly higher in responding tumors compared with non-responding ones (P=0.0379). Patients with FDXR values above the cutoff value of 13.52 had a statistically longer survival than those with FDXR gene expressions below the cutoff value (P=0.0148). The 9 tumors with wild-type p53 had statistically higher FDXR gene expressions than the 14 tumors with mutant-type p53 which had sequence alterations within the "hot ...Continue Reading

References

Mar 10, 1995·Archives of Biochemistry and Biophysics·R RapoportI Hanukoglu
Nov 1, 1995·Current Opinion in Oncology·S W Lowe
Feb 21, 1996·Journal of the National Cancer Institute·S SjögrenJ Bergh
Aug 3, 1999·The Journal of Clinical Investigation·F BunzB Vogelstein
Mar 4, 2000·Free Radical Biology & Medicine·R G Allen, M Tresini
Oct 18, 2000·Free Radical Biology & Medicine·J ChandraS Orrenius
Mar 21, 2002·Nature Reviews. Cancer·T Soussi, C Béroud
Mar 6, 2003·Human Mutation·Barry Iacopetta
May 2, 2003·Nature Reviews. Cancer·Daniel B LongleyPatrick G Johnston
Feb 4, 2005·The New England Journal of Medicine·Jeffrey A Meyerhardt, Robert J Mayer
Sep 21, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio RussoUNKNOWN TP53-CRC Collaborative Study Group

❮ Previous
Next ❯

Citations

Mar 6, 2008·The Journal of Biological Chemistry·Francesco TrapassoCarlo M Croce
Aug 18, 2010·Antioxidants & Redox Signaling·Lorenzo GalluzziGuido Kroemer
Jun 19, 2010·International Journal of Cancer. Journal International Du Cancer·Stefania NobiliEnrico Mini
Oct 16, 2007·Journal of Proteome Research·Simona FontanaGiacomo De Leo
Dec 23, 2020·Recent Patents on Anti-cancer Drug Discovery·Sankha Bhattacharya

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis